These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 30634204)

  • 1. [Effect of Rhubarb Combined Medicinal Activated Carbon on Levels of Serum Phosphorus, Calci- um-Phosphorus Product, and Parathyroid Hormone in Hemodialysis Patients with Hyperphosphatemia].
    Xu Q; Gong JH; Yuan H; Qin YF; Liu JJ; Lu L; Gao D
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2016 Jul; 36(7):797-800. PubMed ID: 30634204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensified treatment of hyperphosphatemia associated with reduction in parathyroid hormone in patients on maintenance hemodialysis.
    Chen L; He JX; Chen YY; Ling YS; Lin CH; Guan TJ
    Ren Fail; 2018 Nov; 40(1):15-21. PubMed ID: 29295646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical effects of the new phosphorus binder, bixalomer in hemodialysis patients switched from sevelamer hydrochloride.
    Gen S; Sasaki T; Saito K; Nobe K; Nodaira Y; Ikeda N
    Ther Apher Dial; 2014 Jun; 18 Suppl 2():8-12. PubMed ID: 24975889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of nicotinamide in the management of hyperphosphatemia in pediatric patients on regular hemodialysis.
    El Borolossy R; El Wakeel LM; El Hakim I; Sabri N
    Pediatr Nephrol; 2016 Feb; 31(2):289-96. PubMed ID: 26420678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of efficacy of the phosphate binders nicotinic acid and sevelamer hydrochloride in hemodialysis patients.
    Ahmadi F; Shamekhi F; Lessan-Pezeshki M; Khatami MR
    Saudi J Kidney Dis Transpl; 2012 Sep; 23(5):934-8. PubMed ID: 22982903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
    Navaneethan SD; Palmer SC; Craig JC; Elder GJ; Strippoli GF
    Am J Kidney Dis; 2009 Oct; 54(4):619-37. PubMed ID: 19692157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous alfacalcidol once versus twice or thrice weekly in hemodialysis patients.
    Alghareeb A; Sabry A; Bawadekji H; Alsaran K
    Ther Apher Dial; 2013 Feb; 17(1):30-4. PubMed ID: 23379490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nicotinamide suppresses hyperphosphatemia in hemodialysis patients.
    Takahashi Y; Tanaka A; Nakamura T; Fukuwatari T; Shibata K; Shimada N; Ebihara I; Koide H
    Kidney Int; 2004 Mar; 65(3):1099-104. PubMed ID: 14871431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use.
    Copland M; Komenda P; Weinhandl ED; McCullough PA; Morfin JA
    Am J Kidney Dis; 2016 Nov; 68(5S1):S24-S32. PubMed ID: 27772640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis.
    Itoh K; Tanaka M; Hashiguchi J; Funakoshi S; Nakano H; Kubo H; Kono T; Uchino J; Masaki K; Date T; Shigematsu T;
    Ther Apher Dial; 2008 Apr; 12(2):126-32. PubMed ID: 18387160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of phosphate binders in adult patients with end stage renal disease receiving hemodialysis: a systematic review.
    Gasu V; Ashong M; Seferi A; Fitzpatrick A
    JBI Database System Rev Implement Rep; 2019 Jan; 17(1):49-73. PubMed ID: 30204711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The influence of short-term magnesium carbonate treatment on calcium-phosphorus balance in dialysis patients].
    Zwiech R; Dryja P; Łacina D; Króliczak V; Chrul S; Kacprzyk F
    Wiad Lek; 2011; 64(1):9-14. PubMed ID: 21812357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of hyperphosphatemia with bixalomer in Japanese patients on long-term hemodialysis with gastrointestinal symptoms.
    Ito K; Takeshima A; Shishido K; Wakasa M; Kumata C; Matsuzaka K; Nakajima Y; Ogata H
    Ther Apher Dial; 2014 Jun; 18 Suppl 2():19-23. PubMed ID: 24975891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of oral ferric citrate on serum phosphorus in hemodialysis patients: multicenter, randomized, double-blind, placebo-controlled study.
    Lee CT; Wu IW; Chiang SS; Peng YS; Shu KH; Wu MJ; Wu MS
    J Nephrol; 2015 Feb; 28(1):105-13. PubMed ID: 24840781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group.
    Slatopolsky EA; Burke SK; Dillon MA
    Kidney Int; 1999 Jan; 55(1):299-307. PubMed ID: 9893140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.
    Block GA; Martin KJ; de Francisco AL; Turner SA; Avram MM; Suranyi MG; Hercz G; Cunningham J; Abu-Alfa AK; Messa P; Coyne DW; Locatelli F; Cohen RM; Evenepoel P; Moe SM; Fournier A; Braun J; McCary LC; Zani VJ; Olson KA; Drüeke TB; Goodman WG
    N Engl J Med; 2004 Apr; 350(15):1516-25. PubMed ID: 15071126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of low-dose lanthanum carbonate on calcium and phosphorus metabolism in Asian Patients with end-stage renal disease, maintenance hemodialysis and hyperphosphatemia.
    Cui X; Jiang S; Liu L; Tang X; Chen Y
    Afr Health Sci; 2022 Jun; 22(2):362-368. PubMed ID: 36407374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
    Van Buren PN; Lewis JB; Dwyer JP; Greene T; Middleton J; Sika M; Umanath K; Abraham JD; Arfeen SS; Bowline IG; Chernin G; Fadem SZ; Goral S; Koury M; Sinsakul MV; Weiner DE;
    Am J Kidney Dis; 2015 Sep; 66(3):479-88. PubMed ID: 25958079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and safety of extended-release nicotinic acid for reducing serum phosphorus in hemodialysis patients.
    Aramwit P; Srisawadwong R; Supasyndh O
    J Nephrol; 2012; 25(3):354-62. PubMed ID: 21748722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-finding study of bixalomer in patients with chronic kidney disease on hemodialysis with hyperphosphatemia: a double-blind, randomized, placebo-controlled and sevelamer hydrochloride-controlled open-label, parallel group study.
    Akizawa T; Origasa H; Kameoka C; Kaneko Y; Kanoh H
    Ther Apher Dial; 2014 Jun; 18 Suppl 2():24-32. PubMed ID: 24975892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.